210 related articles for article (PubMed ID: 26091680)
1. Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
Lamanna N
Oncology (Williston Park); 2015 Jun; 29(6):443, 445. PubMed ID: 26091680
[No Abstract] [Full Text] [Related]
2. B-cell receptor inhibitors in chronic lymphocytic leukemia.
Flinn IW
Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
[No Abstract] [Full Text] [Related]
3. Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Godet S; Protin C; Dupuis J; Dartigeas C; Bastie JN; Herbaux C; Leblond V; de Guibert S; Ghez D; Brion A; Ysebaert L; Delmer A; Quinquenel A
Am J Hematol; 2018 Feb; 93(2):E52-E54. PubMed ID: 29164674
[No Abstract] [Full Text] [Related]
4. Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
Mato AR; Samp JC; Gauthier G; Terasawa E; Brander DM
Cancer Biol Ther; 2018 Jul; 19(7):636-643. PubMed ID: 29584544
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Danilov AV
Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib, ibrutinib show benefits in CLL.
Cancer Discov; 2014 Apr; 4(4):382. PubMed ID: 24706642
[No Abstract] [Full Text] [Related]
7. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG
J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983
[TBL] [Abstract][Full Text] [Related]
8. Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Molica S
Expert Rev Hematol; 2015 Jun; 8(3):277-81. PubMed ID: 25804936
[TBL] [Abstract][Full Text] [Related]
9. Idelalisib for chronic lymphocytic leukemia.
Brown JR
Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
[No Abstract] [Full Text] [Related]
10. The use of ibrutinib in chronic lymphocytic leukemia.
Damon LE
Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
[No Abstract] [Full Text] [Related]
11. Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Pospisilova S; Sutton LA; Malcikova J; Tausch E; Rossi D; Montserrat E; Moreno C; Stamatopoulos K; Gaidano G; Rosenquist R; Ghia P;
Haematologica; 2016 Mar; 101(3):263-5. PubMed ID: 26928246
[No Abstract] [Full Text] [Related]
12. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
13. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Desai AV; El-Bakkar H; Abdul-Hay M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):314-22. PubMed ID: 25445466
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
Burger JA
Curr Hematol Malig Rep; 2012 Mar; 7(1):26-33. PubMed ID: 22105489
[TBL] [Abstract][Full Text] [Related]
15. B cell receptor inhibition as a target for CLL therapy.
Jeyakumar D; O'Brien S
Best Pract Res Clin Haematol; 2016 Mar; 29(1):2-14. PubMed ID: 27742069
[TBL] [Abstract][Full Text] [Related]
16. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
[TBL] [Abstract][Full Text] [Related]
17. Clonal dynamics in chronic lymphocytic leukemia.
Gutierrez C; Wu CJ
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):466-475. PubMed ID: 31808879
[TBL] [Abstract][Full Text] [Related]
18. [Targeted treatment of chronic lymphocytic leukaemia].
Niemann CU
Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
[TBL] [Abstract][Full Text] [Related]
19. Survival adjusting for crossover: phase 3 study of ibrutinib
Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
[No Abstract] [Full Text] [Related]
20. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]